[go: up one dir, main page]

BRPI0814115B8 - composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto - Google Patents

composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto

Info

Publication number
BRPI0814115B8
BRPI0814115B8 BRPI0814115A BRPI0814115A BRPI0814115B8 BR PI0814115 B8 BRPI0814115 B8 BR PI0814115B8 BR PI0814115 A BRPI0814115 A BR PI0814115A BR PI0814115 A BRPI0814115 A BR PI0814115A BR PI0814115 B8 BRPI0814115 B8 BR PI0814115B8
Authority
BR
Brazil
Prior art keywords
compound
deoxy
pharmaceutical composition
stabilizing
prostaglandin
Prior art date
Application number
BRPI0814115A
Other languages
English (en)
Inventor
Kawasaki Junichi
Ueno Ryuji
Harada Yasuhiro
Nishimura Yoshie
Original Assignee
R Tech Ueno Ltd
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd, Sucampo Ag filed Critical R Tech Ueno Ltd
Publication of BRPI0814115A2 publication Critical patent/BRPI0814115A2/pt
Publication of BRPI0814115B1 publication Critical patent/BRPI0814115B1/pt
Publication of BRPI0814115B8 publication Critical patent/BRPI0814115B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto. a presente invenção refere-se a uma composição farmacêutica compreendendo um composto de 11-deóxi-prostaglandina representada pela fórmula (i): (i) e um éster de ácido graxo. misturando-se o composto de fórmula (i) e um éster de ácido graxo, o composto de fórmula (i) será estabilizado.
BRPI0814115A 2007-07-19 2008-07-16 composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto BRPI0814115B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92994807P 2007-07-19 2007-07-19
US60/929,948 2007-07-19
PCT/JP2008/063222 WO2009011449A2 (en) 2007-07-19 2008-07-16 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound

Publications (3)

Publication Number Publication Date
BRPI0814115A2 BRPI0814115A2 (pt) 2015-02-03
BRPI0814115B1 BRPI0814115B1 (pt) 2019-04-02
BRPI0814115B8 true BRPI0814115B8 (pt) 2021-05-25

Family

ID=39720491

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814115A BRPI0814115B8 (pt) 2007-07-19 2008-07-16 composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto

Country Status (14)

Country Link
US (2) US8969324B2 (pt)
EP (2) EP2178516B1 (pt)
JP (2) JP5390519B2 (pt)
KR (1) KR101485212B1 (pt)
CN (2) CN103393618A (pt)
AU (1) AU2008276840B2 (pt)
BR (1) BRPI0814115B8 (pt)
CA (1) CA2691995C (pt)
IL (1) IL203064B (pt)
MX (1) MX339727B (pt)
NZ (2) NZ583203A (pt)
RU (3) RU2506072C2 (pt)
TW (2) TWI552772B (pt)
WO (1) WO2009011449A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1978944E (pt) * 2006-01-24 2012-11-26 Sucampo Ag Formulação em cápsula de gelatina mole
BR112014002712A8 (pt) * 2011-08-05 2017-06-20 Sucampo Ag método para tratamento da esquizofrenia
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
JP6580414B2 (ja) * 2015-08-07 2019-09-25 小林製薬株式会社 生薬末含有錠剤
US10716544B2 (en) 2015-10-08 2020-07-21 Zmk Medical Technologies Inc. System for 3D multi-parametric ultrasound imaging
CN108619107A (zh) * 2018-05-28 2018-10-09 青海制药厂有限公司 一种含鲁比前列酮的软胶囊及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU36479A1 (pt) * 1958-02-12
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
US4310543A (en) * 1980-10-09 1982-01-12 Hoffmann-La Roche Inc. Prostaglandin compositions
US4301175A (en) * 1980-12-29 1981-11-17 The Upjohn Company E-Type prostaglandin compositions
US4431833A (en) * 1982-12-27 1984-02-14 American Cyanamid Company Prostaglandin and hydroxylated fatty acid ester formulations
KR920007569B1 (ko) * 1984-11-30 1992-09-07 쥬우가이 세이야꾸 가부시끼가이샤 프로스타글란딘 e 유도체의 안정한 제제의 제조방법
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US6183466B1 (en) * 1998-08-21 2001-02-06 Alza Corporation Dosage form comprising a capsule
ATE402925T2 (de) * 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
JP4995407B2 (ja) * 2002-04-25 2012-08-08 バナー ファーマキャップス， インコーポレーテッド 咀嚼可能なソフトカプセル
FR2850275B1 (fr) * 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
DE602004015507D1 (de) * 2004-02-17 2008-09-11 Symrise Gmbh & Co Kg Überzogene, sphärische, nahtlose, gefüllte kapseln
EP1841433B1 (en) * 2005-01-27 2011-11-30 Sucampo AG Composition for treating central nervous system disorders
AR055038A1 (es) * 2005-03-04 2007-08-01 Sucampo Ag Metodo y compuesto para tratar enfermedades vasculares perifericas
PT1978944E (pt) 2006-01-24 2012-11-26 Sucampo Ag Formulação em cápsula de gelatina mole

Also Published As

Publication number Publication date
US20150126609A1 (en) 2015-05-07
KR20100053563A (ko) 2010-05-20
KR101485212B1 (ko) 2015-01-22
RU2013135403A (ru) 2015-02-10
EP2327398A2 (en) 2011-06-01
RU2010105847A (ru) 2011-08-27
BRPI0814115B1 (pt) 2019-04-02
JP2010533707A (ja) 2010-10-28
CN103393618A (zh) 2013-11-20
RU2651471C2 (ru) 2018-04-19
WO2009011449A2 (en) 2009-01-22
US20090022787A1 (en) 2009-01-22
CA2691995C (en) 2016-04-26
BRPI0814115A2 (pt) 2015-02-03
NZ595270A (en) 2013-04-26
TWI552772B (zh) 2016-10-11
JP2014001247A (ja) 2014-01-09
NZ583203A (en) 2011-10-28
RU2506072C2 (ru) 2014-02-10
CN101808623B (zh) 2013-08-14
AU2008276840A1 (en) 2009-01-22
AU2008276840B2 (en) 2013-10-03
TWI446912B (zh) 2014-08-01
EP2178516B1 (en) 2015-09-09
IL203064B (en) 2018-02-28
TW200911273A (en) 2009-03-16
EP2327398A3 (en) 2014-05-21
MX2010000693A (es) 2010-06-01
CA2691995A1 (en) 2009-01-22
TW201436824A (zh) 2014-10-01
US8969324B2 (en) 2015-03-03
MX339727B (es) 2016-06-06
WO2009011449A3 (en) 2010-04-29
EP2178516A2 (en) 2010-04-28
JP5390519B2 (ja) 2014-01-15
US9254326B2 (en) 2016-02-09
CN101808623A (zh) 2010-08-18
RU2018113296A (ru) 2019-10-14

Similar Documents

Publication Publication Date Title
BR112012017564A2 (pt) Formulação antimicrobiana
BR112013023847A2 (pt) composições farmacêuticas compreendendo ésteres de sorbitano
BR112013003332A2 (pt) método para melhorar a estabilidade de intensificador de doce e composição contendo intensificador de doce estabilizado
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
BR112013006936A2 (pt) composto de amida substituída
BR112012000968B8 (pt) composto, composição e método para inibir uma fosfatidil inositol-3 cinase.
EA201170772A1 (ru) Органические соединения
BR112013017635A2 (pt) inibidores de cyp11b, cyp17 e/ou cyp21
BR112015001618A2 (pt) composições fungicidas
GEP20156266B (en) Spiroheterocyclic n-oxypiperidines as pesticides
BR112012028369A2 (pt) processo de preparo de aminoácidos ou ésteres saturados, compreendendo uma etapa de metástase.
WO2009129545A8 (en) Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
NZ609527A (en) N1/n2-lactam acetyl-coa carboxylase inhibitors
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
EA201270216A1 (ru) Фармацевтический состав
BRPI0702269A (pt) alcanolamidas e uso do mesmo como aditivos de combustìvel
MX340125B (es) 2-hidroxi-4-(metiltio) butironitrilo estable en almacenamiento.
WO2009097113A3 (en) Oxazole and thiazole compounds as b-catenin modulators and uses thereof
BR112014009376A2 (pt) composições
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
BRPI0814115B8 (pt) composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto
BR112012023317A2 (pt) hidrato de cloridrato de agomelatina e sua preparação
MA32721B1 (fr) Composition pharmaceutique solide
BR112013028486A2 (pt) método para promover crescimento de planta

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2467 DE 17/04/2018 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF